Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…Using a Dopamine Genetic Risk Score to Predict Impulse Control Behaviours for Parkinson’s Disease Patients
Objective: The current study aimed to utilise a dopamine genetic risk score and objective laboratory-based behavioural measures of impulse control to identify Parkinson’s patients most…Distinct oscillatory fingerprints in dyskinesias mediated by D1 versus D2 receptors
Objective: To characterize the patterns of cortico-basal ganglia oscillations induced by D1 or D2 receptor agonists in a rat model of L-DOPA-induced dyskinesia. Background: In…Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report
Objective: To describe the case of a patient with Parkinson’s disease (PD) who suffered from a rapid deterioration of his oral health status following treatment…Do Parkinson’s disease medications have an effect on gut microbiome? A case-control study
Objective: To investigate the difference in the gut microbiota between drug-naïve and medicated PD patients and focus on the association between gut microbiota and anti-PD medications. Background:…A neurophysiological profile associated with impulse control disorders in Parkinson’s disease
Objective: To get new insights into the role of oscillatory brain activity recorded non-invasively in patients with Parkinson’s disease (PD) and impulse control disorders (ICDs).…Frequency and risk factors of dopamine agonist-induced peripheral edema in patients with Parkinson’s disease
Objective: To determine the frequency and risk factors of peripheral edema (PE) development and whether discontinuation of the drug is enough for treatment. To determine…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson’s disease: A prospective analysis of Thai Apomorphine Registry
Objective: To evaluate a reduction of LED in PD patients who achieve satisfactory motor control with long-term continuous subcutaneous apomorphine infusion (CSAI) Background: Apomorphine is…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 15
- Next Page »